Healthcare / Medical Instruments & SuppliesTaipei Exchange
$5.15
-0.05 (-0.93%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 16%
FCF escenarios
weak_data · normalized FCF $-39.1M · quality 36.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
11/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$758M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-56.2%
↓Gross Margin
-6.7%
↓Debt/Equity
0.82
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-8.1%
FCF CAGR
—
FCF margin
-38.2%
FCF / Net income
0.89x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $641.1M · net income $-274.0M · FCF $-244.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $641.1M | $641.1M | $909.4M | $845.7M | $825.4M |
| Net Income | $-274.0M | $-274.0M | $-174.1M | $248.9M | $-253.6M |
| EBITDA | $-203.9M | $-203.9M | $-56.3M | $382.7M | $-103.2M |
| EPS | — | — | -1.18 | 1.67 | -1.72 |
| Gross Margin | -6.7% | -6.7% | 10.2% | 11.7% | 2.3% |
| Operating Margin | -37.4% | -37.4% | -14.1% | -13.8% | -25.6% |
| Net Margin | -42.7% | -42.7% | -19.1% | 29.4% | -30.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.82 | 0.82 | 0.40 | 0.30 | 0.46 |
| Current Ratio | 1.41 | 1.41 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-244.9M | $-244.9M | $-39.1M | $-22.6M | $15.3M |
| Returns | |||||
| ROE | -56.2% | -56.2% | -22.7% | 26.6% | -36.8% |
| Valuation | |||||
| P/E | — | — | — | 6.20 | — |
| EV/EBITDA | — | — | — | 4.14 | — |
| P/B | 1.56 | 1.56 | 2.64 | 1.65 | 1.87 |
| Growth & Yield | |||||
| Revenue Growth | -29.5% | -29.5% | 7.5% | 2.5% | — |
| EPS Growth | — | — | -170.7% | 197.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-32.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.18 → n/d
Residual
-32.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.